Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models

Endocrine-Related Cancer

Volumn 19, Issue 4, 2012, Pages 527-539

  Mariniello, Barbara ^a   Rosato, Antonio ^b,c   Zuccolotto, Gaia ^b   Rubin, Beatrice ^a   Cicala, Maria Verena ^a   Finco, Isabella ^a   Iacobone, Maurizio ^b   Frigo, Anna Chiara ^b   Fassina, Ambrogio ^b   Pezzani, Raffaele ^a   Mantero, Franco ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; EVEROLIMUS; HYDROCORTISONE; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADENOMA; ADRENAL CORTEX; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ADENOMA; ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADULT; AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MICE; MICE, KNOCKOUT; MICE, SCID; MIDDLE AGED; PYRIDINES; SIROLIMUS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84864408099     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0337     Document Type: Article

References (42)

1. Abramoff MD, Magalhaes PJ & Ram SJ 2004 Image processing with ImageJ. Biophotonics International 11 36-42.
2. Agarwala SS & Case S 2010 Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist 15 236-245. (doi:10.1634/theoncologist.2009-0141)
3. Albiger NM, Occhi G, Mariniello B, Iacobone M, Favia G, Fassina A, Faggian D, Mantero F & Scaroni C 2007 Food-dependent Cushing's syndrome: from molecular characterization to therapeutical results. European Journal of Endocrinology 157 771-778. (doi:10.1530/EJE-07-0253)
4. Allolio B & Fassnacht M 2006 Clinical review: adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism 91 2027-2037. (doi:10.1210/jc.2005-2639)
5. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G & Mercurio AM 2001 Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Research 61 5736-5740.
6. Bernini GP, Moretti A, Bonadio AG, Menicagli M, Viacava P, Naccarato AG, Iacconi P, Miccoli P & Salvetti A 2002 Angiogenesis in human normal and pathologic adrenal cortex. Journal of Clinical Endocrinology and Metabolism 87 4961-4965. (doi:10.1210/jc.2001-011799)
7. Butler C, Butler WM & Rizvi AA 2009 Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocrine Practice 26 1-19. (doi:10.4158/EP09295.CR)
8. Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D & Harris AL 1997 Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Research 57 5281-5285.
9. De Martino MC, van Koetsveld PM, Pivonello R & Hofland LJ 2010 Role of the mTOR pathway in normal and tumoral adrenal cells. Neuroendocrinology 92 (Suppl 1) 28-34. (doi:10.1159/000314280)
10. Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, Zhao W, Peralta-Del Valle MH, Figueiredo BC, Zambetti GP & Lalli E 2010 Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Research 70 4666-4675. (doi:10.1158/0008-5472.CAN-09-3970)
11. Fasolo A & Sessa C 2008 mTOR inhibitors in the treatment of cancer. Expert Opinion on Investigational Drugs 17 1717-1734. (doi:10.1517/13543784.17. 11.1717)
12. Feige JJ 2009 Angiogenesis in adrenocortical physiology and tumor development. Annales d'Endocrinologie 70 153-155. (doi:10.1016/j.ando.2009.02. 005)
13. Ferrara N & Davis-Smyth T 1997 The biology of vascular endothelial growth factor. Endocrine Reviews 18 4-25. (doi:10.1210/er.18.1.4)
14. Ferrara N, Gerber HP & LeCouter J 2003 The biology of VEGF and its receptors. Nature Medicine 9 669-676. (doi:10.1038/nm0603-669)
15. de Fraipont F, El Atifi M, Gicquel C, Bertagna X, Chambaz EM & Feige JJ 2000 Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. Journal of Clinical Endocrinology and Metabolism 85 4734-4741. (doi:10.1210/jc.85.12.4734)
16. de Fraipont F, El Atifi M, Cherradi N, LeMoigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E et al. 2005 Gene expression prolifing of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. Journal of Clinical Endocrinology and Metabolism 90 1819-1829. (doi:10.1210/jc.2004-1075)
17. Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, Gonzalez FJ & Fabra A 2004 Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. Journal of Investigative Dermatology 123 1151-1161. (doi:10.1111/j.0022-202X.2004.23460.x)
18. Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC et al. 2003 Managment of the clinically inapparent adrenal mass (incidentaloma). Annals of Internal Medicine 138 424-429. (doi:10.3275/7324)
19. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M et al. 2002 Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Medicine 8 128-135. (doi:10.1038/nm0202-128)
20. Hanahan D & Folkman J 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 353-364. (doi:10.1016/S0092- 8674(00)80108-7)
21. Heikkilä P, Arola J, Voutilainen R, Salmenkivi K, Kahri AI & Liu J 2000 Expression of vascular endothelial growth factor in human adrenals. Endocrine Research 26 867-871. (doi:10.3109/07435800009048610)
22. Houghton PJ 2010 Everolimus. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 16 1368-1372. (doi:10.1158/1078-0432.CCR-09-1314)
23. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Thng CH, Chow P, Ong HS, Chung A & Soo KC 2009 Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. Journal of Cellular and Molecular Medicine 13 2673-2683. (doi:10.1111/j.1582-4934.2009.00692.x)
24. Keating GM & Santoro A 2009 Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69 223-240. (doi:10.2165/00003495- 200969020-00006)
25. Keyaerts M, Verschueren J, Bos TJ, Tchouate-Gainkam LO, Peleman C, Breckpot K, Vanhove C, Caveliers V, Bossuyt A & Lahoutte T 2008 Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission. European Journal of Nuclear Medicine and Molecular Imaging 35 999-1007. (doi:10.1007/s00259-007-0664-2)
26. Leung DW, Cachianes G, Kuang WJ, Goeddel DV & Ferrara N 1989 Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 1306-1309. (doi:10.1126/science.2479986)
27. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M & Carter C 2006 Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research 66 11851-11858. (doi:10.1158/0008-5472.CAN-06-1377)
28. Mabuchi S, Altomare DA, CheungM, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF & Testa JR 2007a RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 13 4261-4270. (doi:10.1158/1078-0432. CCR-06-2770)
29. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC & Testa JR 2007b RAD001(everolimus), delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Research 67 2408-2413. (doi:10.1158/0008-5472.CAN-06-4490)
30. Mariniello B, Finco I, Sartorato P, Patalano A, Iacobone M, Guzzardo V, Fassina A & Mantero F 2010 Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells. Journal of Endocrinological Investigation 70 4666-4675.
31. Masood R, Cai J, Zheng T, Smith DL, Hinton DR & Gill PS 2001 Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98 1904-1913. (doi:10.1182/blood.V98.6. 1904)
32. Rahmani M, Davis EM, Bauer C, Dent P & Grant S 2005 Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. Journal of Biological Chemistry 280 35217-35227. (doi:10.1074/jbc.M506551200)
33. Shibusa T, Shijubo N & Abe S 1998 Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 4 1483-1487.
34. Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE & Lu B 2005 Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24 5414-5422. (doi:10.1038/sj.onc.1208715)
35. Shweiki D, Itin A, Neufeld G, Gitay-Goren H & Keshet E 1993 Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. Journal of Clinical Investigation 91 2235-2243. (doi:10.1172/JCI116450)
36. Wey JS, Stoeltzing O & Ellis LM 2004 Vascular endothelial growth factor receptors: expression and function in solid tumors. Clinical Advances in Hematology and Oncology 2 37-45.
37. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 64 7099-7109. (doi:10.1158/0008-5472.CAN-04-1443)
38. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R & Kelley S 2006 Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews Drug Discovery 5 835-844. (doi:10.1038/nrd2130)
39. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM & Lynch M 2008 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics 7 3129-3140. (doi:10.1158/1535-7163.MCT-08-0013)
40. Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, Allolio B & Fassnacht M 2010 Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. European Journal of Endocrinology 162 349-356. (doi:10.1530/EJE-09-0804)
41. Xu YZ, Zhu Y, Shen ZJ, Sheng JY, He HC, Ma G, Qi YC, Zhao JP, Wu YX, Rui WB et al. 2011 Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy. Endocrine 40 445-451. (doi:10.1007/s12020-011-9502-1)
42. Zacharieva S, Atanassova I, Nachev E, Orbetzova M, Kirilov G, Kalinov K & Shigarminova R 2005 Markers of vascular function in hypertension due to Cushing's syndrome. Hormone and Metabolic Research 37 36-39. (doi:10.1055/s-2005-861031)